ArriVent Reports 2025 Results, Plans Phase 3 Data for Firmonertinib
NEWTOWN SQUARE, PA — ArriVent BioPharma Inc. (Nasdaq: AVBP) reported financial results for the year ended December 31, 2025, and said it expects pivotal Phase 3 data for its lung …
ArriVent Reports 2025 Results, Plans Phase 3 Data for Firmonertinib Read More